Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Background: The prognostic significance of breakpoint cluster region gene-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcripts in chronic myeloid leukemia (CML) is still controversial.Patients and Methods: All consecutive CML patients in chronic phase treated with imatinib in a si...
| Publicado en: | Clinical Lymphoma, Myeloma & Leukemia Vol. 17; no. 11; pp. 728 - 734 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Elsevier B.V.
Nov2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125944862&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 125944862 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 21522650 B54U jtl: Clinical Lymphoma, Myeloma & Leukemia issn: 21522650 maglogo: N pubinfo: dt: Nov2017 vid: 17 iid: 11 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 125944862 125944862 NLM28822797 125944862 10.1016/j.clml.2017.06.009 NLM28822797 125944862 ppf: 728 ppct: 6 formats: tig: atl: Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib. aug: au: Pagnano, Katia Borgia Barbosa Miranda, Eliana Cristina Delamain, Márcia Torresan Duarte, Gislaine Oliveira de Paula, Erich Vinicius Lorand-Metze, Irene de Souza, Carmino Antonio affil: Hematology and Hemotherapy Center, University of Campinas, Campinas, São Paulo, Brazil sug: subj: Leukemia, Myeloid, Chronic Drug Therapy Female Human Prognosis Leukemia, Myeloid, Chronic Mortality Leukemia, Myeloid, Chronic Pathology Middle Age Aged Treatment Outcomes Survival Analysis Young Adult Adult Aged, 80 and Over Male Middle Aged: 45-64 years Aged: 65+ years Adult: 19-44 years Aged, 80 & over Female Male ab: Background: The prognostic significance of breakpoint cluster region gene-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcripts in chronic myeloid leukemia (CML) is still controversial.Patients and Methods: All consecutive CML patients in chronic phase treated with imatinib in a single center were analyzed (n = 170). BCR-ABL1 transcript was evaluated using multiplex reverse transcription polymerase chain reaction. Exclusively patients with BCR-ABL transcripts e13a2 and/or e14a2 were included in this analysis.Results: Patients with e14a2 transcripts presented higher rates of optimal molecular responses at 3 months and higher rates of complete cytogenetic response (CCR) at 6 months. E13a2, e14a2, and e14a2 with e13a2 (e14a2+e13a2) groups presented similar rates of 5-year event-free, progression-free, and overall survival. There was a superior 10-year overall survival in patients with transcripts e13a2 compared with e14a2 (alone or coexpressed with e13a2; 93% vs. 73%; P = .03), although the 5-year overall survival was 96% vs. 88%, respectively (P = not significant). In a multivariate analysis, high/intermediate Sokal score and e14a3/e14a3+e14a2 were independent factors for poor overall survival (hazard risk [HR], 4.63; P = .023 for Sokal score and HR, 10.6; P = .041 for BCR-ABL transcript).Conclusion: Patients with BCR-ABL transcripts e14a2 transcripts have higher rates of CCR at 6 months and higher rates of optimal molecular response at 3 months compared with e13a2 or with both transcripts, but no difference in 5-year overall, progression-free, and event-free survival. There was a superior 10-year overall survival among patients with transcripts e13a2 compared with e14a2 (alone or coexpressed with e13a2). pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|